Oncoinvent ASA: Oncoinvent presents 3Q company update in live webcast
2026-10-28 07:04:00
Oslo, Norway, 28 October 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is hosting a live webcast at 10:00 AM CET today, Wednesday, 28 October 2026.
- Presenters: CEO Øystein Soug, CFO Ramzi Amri, CMO Zuzana Jirakova Trnkova
- Time: 10:00am CET
- Webcast link: https://qcnl.tv/p/8awn9AmyNjOd67OuY7TwRQ
Highlights:
- Recruited 16 patients into the ovarian Phase 2 trial, having a total of 71 patients by end 3Q
- Added one more clinical site to Oncoinvent's Phase 2 trial; 11 clinical sites now recruiting
- Published Normal tissue dosimetry results in Journal of Nuclear Medicine
- Presented three abstracts at EANM and ESMO
- Completed successful private placement raising gross proceeds of NOK 148.5 million
- Appointed Dr Zuzana Jirakova Trnkova as Chief Medical Offier
The presentation material and the recording of the webcast will be made available at www.oncoinvent.com.
Oncoinvent reports its financial results on a half-yearly basis, complemented by quarterly business updates to keep stakeholders informed and ensure ongoing transparency.